1
|
Li G, Sun L, Qiu Y, Hou Y, Du L, Zhao K, Qian J, Liu J, Ma T. Efficacy of nano-modified Runji ointment in the treatment of mild and moderate psoriasis with blood dryness syndrome: a study protocol for a double-blind randomized controlled trial. Medicine (Baltimore) 2021; 100:e28178. [PMID: 34967353 PMCID: PMC8718181 DOI: 10.1097/md.0000000000028178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Accepted: 11/19/2021] [Indexed: 01/05/2023] Open
Abstract
INTRODUCTION Psoriasis is a common, recurrent, immune skin disease, which seriously affects patients' quality of life. In clinical practice, modified Runji ointment can effectively treat mild-to-moderate psoriasis with blood dryness syndrome, but there is a lack of high-quality evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of nano-modified Runji ointment in the treatment of mild-to-moderate psoriasis with blood dryness syndrome. METHODS/DESIGN This study will be a randomized double-blind placebo-controlled trial. A total of 80 patients will be recruited and randomly divided into an intervention group (nano-modified Runji ointment group) and a placebo group at a ratio of 1:1. All included patients will receive 8 weeks of nano-modified Runji ointment or placebo ointment respectively, twice a day. The primary outcome will be the change in psoriasis area and disease severity index score at week 8 compared to baseline. The secondary outcomes will be rash area score, pruritus score, Dermatology Life Quality Index score, traditional Chinese medicine symptom score and adverse events. DISCUSSION This study may provide high-quality evidence for the efficacy of nano-modified Runji ointment in the treatment of mild to moderate psoriasis with blood dryness syndrome. The results of this study will be published in peer-reviewed journals. TRIAL REGISTRATION ChiCTR, ChiCTR2000034292. Registered July 1, 2020, https://www.chictr.org.cn/edit.aspx?pid=55884&htm=4.
Collapse
Affiliation(s)
- Guanru Li
- Department of Dermatology, Beijing Traditional Chinese Medicine Hospital Shunyi Hospital, Shunyi District, Beijing, China
| | - Liyun Sun
- Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine, Dongcheng District, Beijing, China
| | - Yue Qiu
- Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine, Dongcheng District, Beijing, China
| | - Yaquan Hou
- Dongcheng District Yongdingmenwai Community Health Center, Beijing, China
| | - Libo Du
- Institute of Chemistry, Chinese Academy of Sciences, Haidian District, Beijing, China
| | - Kaixuan Zhao
- Department of Dermatology, Handan Mingren Hospital, Hebei Province, China
| | - Jiali Qian
- Department of Dermatology, Beijing Traditional Chinese Medicine Hospital Shunyi Hospital, Shunyi District, Beijing, China
| | - Jiuli Liu
- Department of Dermatology, Beijing Traditional Chinese Medicine Hospital Shunyi Hospital, Shunyi District, Beijing, China
| | - Tengfei Ma
- Department of Dermatology, Beijing Traditional Chinese Medicine Hospital Shunyi Hospital, Shunyi District, Beijing, China
| |
Collapse
|
2
|
Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body. ACTAS DERMO-SIFILIOGRAFICAS 2019. [DOI: 10.1016/j.adengl.2019.07.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
|
3
|
Velasco M, González-Fernández D, Rodriguez-Martín M, Sánchez-Regaña M, Pérez-Barrio S. Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body. ACTAS DERMO-SIFILIOGRAFICAS 2019; 110:752-758. [PMID: 31256797 DOI: 10.1016/j.ad.2019.03.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 03/06/2019] [Accepted: 03/10/2019] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Calcipotriol and betamethasone dipropionate (Cal/BD) aerosol foam is more effective in the treatment of plaque psoriasis than earlier formulations incorporating this combination of active ingredients. The aim of this study was to evaluate patient and physician satisfaction with Cal/BD aerosol foam in the treatment of plaque psoriasis on the body. MATERIAL AND METHODS Retrospective observational study of 446 patients with plaque psoriasis affecting no more than 30% of the body surface area who had received treatment with Cal/BD aerosol foam for 4 weeks. The patients rated their satisfaction with the treatment using the TSQM-9 (Treatment Satisfaction Questionnaire for Medication) and the physicians on a 5-point Likert scale. RESULTS Patients were highly satisfied with Cal/BD aerosol in terms of its ability to treat their condition (84%), relieve their symptoms (84.4%), and act rapidly (82.8%). With respect to convenience, the patients gave high ratings to ease of use (91.8%), ease of planning (93.9%), and ease of following instructions (89.9%). Global satisfaction was also high, with 85% of patients expressing that they were satisfied, very satisfied, or extremely satisfied with the treatment. Of the physicians, 85.7% stated that they were quite or very satisfied with the treatment. CONCLUSION Both patients and physicians expressed high satisfaction with the use of Cal/BD aerosol foam for the treatment of plaque psoriasis on the body.
Collapse
Affiliation(s)
- M Velasco
- Servicio de Dermatología, Hospital Arnau de Vilanova, Valencia, España.
| | - D González-Fernández
- Servicio de Dermatología, Hospital Universitario Cabueñes, Gijón, Asturias, España
| | - M Rodriguez-Martín
- Servicio de Dermatología, Dermaten Clínicas, Santa Cruz de Tenerife, España
| | - M Sánchez-Regaña
- Servicio de Dermatología, Clínica Dermacot, Mataró, Barcelona, España
| | - S Pérez-Barrio
- Servicio de Dermatología, Hospital Universitario Basurto, Bilbao, España
| |
Collapse
|
4
|
Puig L, Carretero G. Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam. ACTAS DERMO-SIFILIOGRAFICAS 2019. [DOI: 10.1016/j.adengl.2019.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
5
|
Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, Murray RM, McGuire P, Mondelli V. Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. Biol Psychiatry 2019; 85:35-48. [PMID: 30122288 PMCID: PMC6269125 DOI: 10.1016/j.biopsych.2018.06.016] [Citation(s) in RCA: 77] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 05/30/2018] [Accepted: 06/14/2018] [Indexed: 12/01/2022]
Abstract
BACKGROUND A relationship between non-neurological autoimmune (NNAI) disorders and psychosis has been widely reported but not yet subjected to meta-analysis. We conducted the first meta-analysis examining the association between NNAI disorders and psychosis and investigated the effect of 1) temporality (as determined by study design), 2) psychiatric diagnosis, and 3) specific autoimmune disorders. METHODS Major databases were searched for articles published until April 2018; 31 studies, comprising data for >25 million individuals, were eligible. Using random-effects models, we examined the overall association between all NNAI disorders and psychosis; rheumatoid arthritis was examined separately given the well-established negative association with psychosis. Stratified analyses investigated the effect of temporality, psychiatric diagnosis, and specific NNAI disorders. RESULTS We observed a positive overall association between NNAI disorders and psychosis (odds ratio [OR] = 1.26; 95% confidence interval [CI], 1.12-1.41) that was consistent across study designs and psychiatric diagnoses; however, considerable heterogeneity was detected (I2 = 88.08). Patterns varied across individual NNAI disorders; associations were positive for pernicious anemia (OR = 1.91; 95% CI, 1.29-2.84), pemphigoid (OR = 1.90; 95% CI, 1.62-2.24), psoriasis (OR = 1.70; 95% CI, 1.51-1.91), celiac disease (OR = 1.53; 95% CI, 1.12-2.10), and Graves' disease (OR = 1.33; 95% CI, 1.03-1.72) and negative for ankylosing spondylitis (OR = 0.72; 95% CI, 0.54-0.98) and rheumatoid arthritis (OR = 0.65; 95% CI, 0.50-0.84). CONCLUSIONS While we observed a positive overall association between NNAI disorders and psychosis, this was not consistent across all NNAI disorders. Specific factors, including distinct inflammatory pathways, genetic influences, autoantibodies targeting brain proteins, and exposure to corticosteroid treatment, may therefore underlie this association.
Collapse
Affiliation(s)
- Alexis E. Cullen
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,Address correspondence to Alexis E. Cullen, Ph.D., Department of Psychosis Studies (Box P067), De Crespigny Park, London SE5 8AF, United Kingdom.
| | - Scarlett Holmes
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Thomas A. Pollak
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Graham Blackman
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Dan W. Joyce
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Matthew J. Kempton
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Robin M. Murray
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Philip McGuire
- Department of Psychosis Studies, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| | - Valeria Mondelli
- Department of Psychological Medicine, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research Maudsley Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom
| |
Collapse
|
6
|
Serafino A, Nicotera G, Andreola F, Giovannini D, Zonfrillo M, Sferrazza G, Calcaterra A, De Angelis C, Camponeschi C, Pierimarchi P. Synergistic antiproliferative and differentiating effect of 2,4-monofurfurylidene-tetra-O-methylsorbitol and 4,6-dimethyl-2-(3,4,5-trimethoxyphenylamino)pyrimidine on primary and immortalized keratinocytes. Biomed Pharmacother 2018; 107:155-167. [PMID: 30086462 DOI: 10.1016/j.biopha.2018.07.174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 07/31/2018] [Accepted: 07/31/2018] [Indexed: 10/28/2022] Open
Abstract
Psoriasis is one of the most common chronic autoinflammatory skin disease, associated with hyperproliferation and abnormal differentiation of keratinocytes, inflammation, and angiogenesis. The available treatments for psoriasis are not curative and may have numerous side effects, and topical administration is preferred over systemic therapy due to the reduced systemic burden of the drug. Thus, novel and more efficacious formulations of anti-inflammatory and/or differentiating compounds for topical application could be very useful for the disease management and for improving the quality of life of the patients. Here we evaluated the potential as anti-psoriatic of an equimolar mixture of two compounds, 2,4-Monofurfurylidene-tetra-O-methylsorbitol (Compound A) and 4,6-dimethyl-2-(3,4,5-trimethoxyphenylamino)pyrimidine (Compound B), that, used individually, are known to possess immunomodulating properties (Compound A) and keratolitic and anti-inflammatory activity (Compound B). Human immortalized keratinocyte cell line (HaCaT cells) and primary human keratinocyte cells from adult donor (HEKa) were used as in vitro experimental models. We show that the mix A + B exhibits antiproliferative activity and induces terminal differentiation more efficiently than compounds A and B used individually. We confirm that the compound B is the active ingredient of the mixture and the mainly responsible for anti-psoriatic activity, but the mix A + B is more effective and possesses lower cytotoxicity than the compound B alone. This could be ascribable to the association with compound A, that is known to possess, in addition to the immunomodulating ability, antioxidant and antiradical action. Our results indicate that mix A + B could be a suitable candidate for a new cosmeceutical formulation for topical treatment of psoriasis.
Collapse
Affiliation(s)
- Annalucia Serafino
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy.
| | - Giuseppe Nicotera
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| | - Federica Andreola
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| | - Daniela Giovannini
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| | - Manuela Zonfrillo
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| | - Gianluca Sferrazza
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| | - Andrea Calcaterra
- University of Rome "La Sapienza", Department of Chemistry and Technology of Drugs, Rome, Italy
| | | | | | - Pasquale Pierimarchi
- Institute of Translational Pharmacology, National Research Council of Italy, Rome, Italy
| |
Collapse
|
7
|
Puig L, Carretero G. Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam. ACTAS DERMO-SIFILIOGRAFICAS 2018; 110:115-123. [PMID: 30031488 DOI: 10.1016/j.ad.2018.05.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 05/11/2018] [Accepted: 05/28/2018] [Indexed: 01/05/2023] Open
Abstract
Topical agents are the first-line treatment for mild and moderate psoriasis, but factors such as frequency of administration, organoleptic properties, and the limited short term results can reduce treatment adherence and effectiveness. Innovations in topical treatments are linked not only to the discovery of new molecules, but also to the reformulation of existing active ingredients based on improvements to administration, organoleptic properties, bioavailability, and ease of use. Calcipotriol and betamethasone dipropionate aerosol foam is a new formulation in which the active ingredients are dissolved in a mixture of volatile propellants that evaporate quickly, leaving a supersaturated solution of calcipotriol and betamethasone dipropionate that enhances penetration into the epidermis. In this article, we take a look at the new calcipotriol and betamethasone dipropionate aerosol formulation and briefly review the main evidence supporting the use of topical treatments for psoriasis.
Collapse
Affiliation(s)
- L Puig
- Departamento de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España.
| | - G Carretero
- Departamento de Dermatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España
| |
Collapse
|
8
|
Chorachoo J, Saeloh D, Srichana T, Amnuaikit T, Musthafa KS, Sretrirutchai S, Voravuthikunchai SP. Rhodomyrtone as a potential anti-proliferative and apoptosis inducing agent in HaCaT keratinocyte cells. Eur J Pharmacol 2016; 772:144-51. [DOI: 10.1016/j.ejphar.2015.12.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 12/04/2015] [Accepted: 12/04/2015] [Indexed: 12/25/2022]
|
9
|
Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation. J Dermatol Sci 2014; 74:242-50. [DOI: 10.1016/j.jdermsci.2014.03.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 01/29/2014] [Accepted: 03/03/2014] [Indexed: 11/24/2022]
|
10
|
Naga Sravan Kumar Varma V, Maheshwari PV, Navya M, Reddy SC, Shivakumar HG, Gowda DV. Calcipotriol delivery into the skin as emulgel for effective permeation. Saudi Pharm J 2014; 22:591-9. [PMID: 25561873 PMCID: PMC4281593 DOI: 10.1016/j.jsps.2014.02.007] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Accepted: 02/15/2014] [Indexed: 11/30/2022] Open
Abstract
The objective of this work is to formulate and evaluate an emulgel containing calcipotriol for treatment of psoriasis. Emulgels have emerged as a promising drug delivery system for the delivery of hydrophobic drugs. Isopropyl alcohol and polyethylene glycol have been employed as permeation enhancers. Formulation chart is made with seven formulations, evaluated for physical parameters, drug content, viscosity, thixotropy, spreadability, extrudability, mucoadhesion, diffusion studies, skin irritation test along with short term stability studies. Carbopolis is reported to have a direct influence on appearance and viscosity of final formulation. The photomicroscopic evaluations showed the presence of spherical globules in size range of 10–15 μm. Rheograms revealed that all the formulations exhibited pseudoplastic flow. Optimized formulation (F6) had shown 86.42 ± 2.0% drug release at the end of 8 h study. The release rate through dialysis membrane and rat skin is higher when compared to commercial calcipotriol ointment. Hence it is concluded that calcipotriol can be delivered topically with enhanced penetration properties when formulated as emulgel.
Collapse
Affiliation(s)
- V Naga Sravan Kumar Varma
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| | - P V Maheshwari
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| | - M Navya
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| | - Sharath Chandra Reddy
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| | - H G Shivakumar
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| | - D V Gowda
- Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, Karnataka 570015, India
| |
Collapse
|
11
|
Sánchez-Regaña M, Llambí-Mateos F, Salleras-Redonnet M, Iglesias Sancho M, Collgros Totosaus H, Umbert-Millet P. Compounding as a Current Therapeutic Option in Dermatology. ACTAS DERMO-SIFILIOGRAFICAS 2013. [DOI: 10.1016/j.adengl.2012.03.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
12
|
Sánchez-Regaña M, Llambí-Mateos F, Salleras-Redonnet M, Iglesias Sancho M, Collgros Totosaus H, Umbert-Millet P. La formulación magistral en la terapéutica dermatológica actual. ACTAS DERMO-SIFILIOGRAFICAS 2013; 104:738-56. [DOI: 10.1016/j.ad.2012.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Revised: 03/01/2012] [Accepted: 03/09/2012] [Indexed: 10/28/2022] Open
|
13
|
Puig L, Carrascosa J, Belinchón I, Fernández-Redondo V, Carretero G, Ruiz-Carrascosa J, Careaga J, de la Cueva P, Gárate M, Ribera M. Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: Consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. ACTAS DERMO-SIFILIOGRAFICAS 2013; 104:488-96. [DOI: 10.1016/j.ad.2012.12.005] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2012] [Revised: 12/10/2012] [Accepted: 12/12/2012] [Indexed: 11/25/2022] Open
|
14
|
Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. ACTAS DERMO-SIFILIOGRAFICAS 2013. [DOI: 10.1016/j.adengl.2012.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
15
|
Jales RD, Nast A, Saconato H, Atallah ÁN, Hirata SH. Topical treatments for scalp psoriasis. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2012. [DOI: 10.1002/14651858.cd009687] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
16
|
Terapia de contacto corto con tazaroteno tópico en Darier segmentaria. ACTAS DERMO-SIFILIOGRAFICAS 2012; 103:255-6. [DOI: 10.1016/j.ad.2011.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2011] [Revised: 09/01/2011] [Accepted: 09/25/2011] [Indexed: 11/15/2022] Open
|
17
|
Sanz-Sánchez T, Díaz-Díaz R, López-Barrantes O, Valverde-Garrido R. Short-Contact Therapy With Topical Tazarotene in Darier Disease. ACTAS DERMO-SIFILIOGRAFICAS 2012. [DOI: 10.1016/j.adengl.2012.04.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
18
|
Markovic BD, Vladimirov SM, Cudina OA, Odovic JV, Karljikovic-Rajic KD. A PAMPA assay as fast predictive model of passive human skin permeability of new synthesized corticosteroid C-21 esters. Molecules 2012; 17:480-91. [PMID: 22222907 PMCID: PMC6268546 DOI: 10.3390/molecules17010480] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2011] [Revised: 12/29/2011] [Accepted: 12/30/2011] [Indexed: 11/18/2022] Open
Abstract
The permeation properties of twenty newly synthesized α-alkoxyalkanoyl and α-aryloxyalkanoyl C-21 esters of standard corticosteroids: Fluocinolone acetonide, dexamethasone, triamcinolone acetonide and hydrocortisone were established using a PAMPA assay (70% silicone oil and 30% isopropyl myristate). The data were compared with parent corticosteroids with addition of mometasone furoate and hydrocortisone acetate. All newly synthesized corticosteroid C-21 esters have effective permeability coefficients higher then -6, mostly followed with high values of retention factors and low permeation. The examined compounds were grouped through relationship between obtained retention factors and permeation parameters (groups I–III). The classification confirmed group I (membrane retentions as well as permeation lower then 30%) for all corticosteroid standards except mometasone furoate, a potent topical corticosteroid which, with high membrane retention (81%) and low permeation (7.7%) fits into group III. The largest number of new synthesized corticosteroids C-21 esters, among them all fluocinolone acetonide C-21 esters, have high membrane retentions (32.4%–86.5%) and low permeations (1.3%–27.1%), fitting in group III. The classification was related to previously obtained anti-inflammatory activity data for the fluocinolone acetonide C-21 esters series. According to the PAMPA results the new synthesized esters could be considered as potential new prodrugs with useful benefit/risk ratio.
Collapse
Affiliation(s)
- Bojan D. Markovic
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia; (S.M.V.); (O.A.C.)
- Author to whom correspondence should be addressed; ; Tel.: +381-113-951-335; Fax: +381-113-972-840
| | - Sote M. Vladimirov
- Author to whom correspondence should be addressed; ; Tel.: +381-113-951-335; Fax: +381-113-972-840
| | - Olivera A. Cudina
- Author to whom correspondence should be addressed; ; Tel.: +381-113-951-335; Fax: +381-113-972-840
| | - Jadranka V. Odovic
- Author to whom correspondence should be addressed; ; Tel.: +381-113-951-335; Fax: +381-113-972-840
| | | |
Collapse
|
19
|
Puig L, Ribera M, Hernanz J, Belinchón I, Santos-Juanes J, Linares M, Querol I, Colomé E, Caballé G. Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. ACTAS DERMO-SIFILIOGRAFICAS 2010. [DOI: 10.1016/j.ad.2010.09.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
20
|
Puig L, Ribera M, Hernanz J, Belinchón I, Santos-Juanes J, Linares M, Querol I, Colomé E, Caballé G. Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. ACTAS DERMO-SIFILIOGRAFICAS 2010. [DOI: 10.1016/s1578-2190(10)70730-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|